Antimicrobial resistance (AMR) is a global threat, particularly given the modest activity in the pipeline of new antimicrobials in development, and emerging resistance to existing antibiotics. In 2016, Lord Jim O’Neill published a globally-focused review on AMR, which highlighted the lack of incentives for new antimicrobial development and encouraged a worldwide system of push’ and pull’ incentives to stimulate new drug development.
Financing AMR innovation discussed globally
BackgroundFinancing of AMR innovation is shifting gears in early 2019. US AMR accelerator CARB-X has expanded its global reach, the Novo REPAIR impact fund reflects on their first and upcoming investments, and the British Government is underway to take first steps for a pull mechanism this year. During the Novel Antimicrobials and AMR Diagnostics conference in mid-March in Berlin, 300 international AMR experts will discuss the status quo.
Encourage development of new antimicrobials
OpinionAntimicrobial resistance (AMR) is a global threat, particularly given the modest activity in the pipeline of new antimicrobials in development, and emerging resistance to existing antibiotics. In 2016, Lord Jim O’Neill published a globally-focused review on AMR, which highlighted the lack of incentives for new antimicrobial development and encouraged a worldwide system of push’ and pull’ incentives to stimulate new drug development.
“We need to grow”
BackgroundWhy the US AMR accelerator aims to expand its reach in Europe to support antibacterial R&D, and why it is important to bundle global resources, explains Kevin Outterson, Executive Director of CARB-X.
AstraZeneca partners with Seres Therapeutics
Latest NewsUnder a three-year agreement, British pharma giant AstraZeneca plc pays €20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response to cancer immune therapies.
AMR: Snipr Biome Aps raises €43m to programme pathogens for death
Latest NewsCopenhagen-based SNIPR BIOME Aps raised €43m in a series A financing led by seed investor Lundbeckfonden Emerge (Copenhagen) and LSP and co-financed by North-East Family Office (Copenhagen) and Wellington Partners (Munich).
Mats Blom joins Modus as CFO
AppointmentsModus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease (SCD), announces the appointment of Mats Blom as Chief Financial Officer (CFO).
Small-molecule acts as broad-band influenza entry blocker
Latest NewsResearchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes.
Seventure starts second microbiome-focussed fund
Latest NewsSeventure Partners has announced the first close of its second microbiome fund designed to put €200m in 20 companies developing microbiome-based health solutions.
Miranda Wolpert joins Wellcome
AppointmentsMiranda Wolpert, MBE, an expert on child and adolescent mental health has joined the London-based Wellcome Trust as head of their mental health priority area.
Numab AG bags CHF70m in licencing deal
Latest NewsSwiss immunology and immuno-oncology specialist Numab Innovation AG has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics Inc.